Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event

Completed

Brief Summary: Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.

Recruitment & Eligibility

Inclusion Criteria

The patient has a high risk of a cardiovascular event as defined by the European guidelines.
The patient is statin-naive (i.e. has not used a statin > 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin.
An LDL-C level is known for the statin-naive patient or for the statin used during visit 1.
It has been decided to start the patient on CRESTOR 5 mg.
The patient is prepared to give permission to the coded data being made available to AstraZeneca

Exclusion Criteria

The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment.
Contraindications for treatment with CRESTOR (see 1 B1 text).
Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial